Marketing-authorisation holder
CSPC Ouyi Pharmaceutical Co., Ltd.
1 medicine in 1 country, as authorisation holder and manufacturer.
Loading your page…
Loading your page…
Marketing-authorisation holder
1 medicine in 1 country, as authorisation holder and manufacturer.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine in the registers under its name, current ones first.
1 medicine
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| CONJUPRI1.25mg base | 2.5mg base | 5mg base · Tablet | Levamlodipine | United States | Not marketed | 2019 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| United States | 1 | 1 | 0 | CompaniesAll medicines |
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Source: U.S. FDA, Drugs@FDA / openFDA. FDA does not endorse this site.
Licence: Public domain (U.S. Government work)
Anvisa, official medicine/API manufacturer factual export, HTTP source version Fri, 09 Oct 2026 08:21:54 GMT, acquired 2026-10-09; exact unmodified native identifiers and fields preserved.
Licence: Brazil federal factual open-data reuse; Decreto 8777/2016 consolidated article 4 and third-party exceptions
Contains information from HSA Listing of Registered Therapeutic Products accessed on 8 October 2026 from data.gov.sg, under Singapore Open Data Licence 1.0: https://data.gov.sg/open-data-licence
Licence: Singapore Open Data Licence
Report an error or request removalCorrections from the company itself are welcome.